Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, up 167% from $1.05 million in the prior-year period. The increase reflects expansion of its CDMO operations, including the February acquisition of Recipharm Israel. The company reported an operating loss of $6.56 million and a net loss of $390,000, with the latter benefiting from a $6.4 million noncash bargain purchase gain related to the acquisition.
Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025, including an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees. The company generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, Scinai expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028. To view the full press release, visit https://ibn.fm/1OlnB.
The revenue growth and order backlog are significant for Scinai, which has been transitioning from a pure-play biotech to a hybrid model with a CDMO business. The Recipharm Israel acquisition has clearly boosted the company's top line and order book, demonstrating the potential of the CDMO strategy. The committed orders provide visibility into future revenue, and the improved cash position, supported by recent financing, extends the company's financial runway. This is crucial for a clinical-stage biotech, as it reduces the risk of near-term dilution and allows the company to advance its immunology pipeline, which includes candidates licensed from the Max Planck Society and PinCell S.r.l. The news may also signal growing demand for CDMO services in Israel, where Scinai operates facilities in Jerusalem and Yavne.
For investors, the update offers a clearer picture of Scinai's financial health and growth trajectory. The company's ability to secure large customer agreements, such as the U.S. deal worth $5.1 million in base fees, underscores its commercial traction. The bargain purchase gain, while noncash, reflects a strategic acquisition at a favorable price. However, the operating loss of $6.56 million highlights ongoing investment in the business. The projected liquidity through late 2027, potentially into 2028, provides a cushion for executing on both the CDMO and therapeutic development fronts. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
The announcement was disseminated through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers services including access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
This news matters because it shows a biotech company successfully diversifying its revenue stream and strengthening its balance sheet, which could serve as a model for other small-cap biotechs facing funding challenges. The growth in committed orders and the extended cash runway may boost investor confidence and support the company's ongoing research and development efforts. For the industry, it highlights the increasing role of CDMOs in the biopharma ecosystem, especially in regions like Israel, and the potential for strategic acquisitions to drive growth.
